Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4831111 | 0.77 | CYP2D6 (0.37) | MEN1KMT2A | |
| SCHEMBL30457629 | 0.71 | MEN1 (0.38) | EPHX2MEN1MAPK1KMT2A | |
| SCHEMBL134689 | 0.68 | ALDH1A1 (0.50) | EPHX2MEN1MAPK1KMT2A | |
| Acetic Acid SCHEMBL703302 | 0.68 | ALDH1A1 (0.46) | EPHX2MEN1MAPK1KMT2A | |
| SCHEMBL21994780 | 0.68 | MEN1 (0.36) | EPHX2MEN1MAPK1KMT2A | |
| SCHEMBL7737714 | 0.67 | EPHX2 (0.40) | EPHX2MEN1MAPK1KMT2A | |
| SCHEMBL133579 | 0.66 | ALDH1A1 (0.54) | EPHX2MEN1KMT2A | |
| SCHEMBL6761013 | 0.66 | CYP2D6 (0.37) | MEN1KMT2A | |
| SCHEMBL9249667 | 0.64 | ALDH1A1 (0.48) | MEN1KMT2A | |
| SCHEMBL27485689 | 0.64 | TSHR (0.36) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3887363-A1 | CYCLIC PENTAMER COMPOUNDS AS PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDER | Novartis AG (CH) | 2021-10-06 | — | — | EP | disclosed |
| WO-2020110008-A1 | CYCLIC PENTAMER COMPOUNDS AS PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDER | NOVARTIS AG (CH) | 2020-06-04 | — | — | WO | disclosed |